1 Executive Summary
1.1 Market overview
1.2 The VTE market will experience minimal growth between 2024 and 2034
1.3 Companies are focusing clinical trial development on factor XI inhibitors
1.4 Optimal treatment strategies for patients with cancer or renal impairment are needed
1.5 REGN-7508 to contribute moderately to sales during the forecast period
1.6 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Diagnosed incident cases of pulmonary embolism, deep vein thrombosis, and VTE
4.4.4 Diagnosed incident cases of deep vein thrombosis by anatomical region
4.4.5 Diagnosed incident cases of VTE by provoking risk factor
4.4.6 Diagnosed incident cases of VTE with cancer as a comorbidity
4.4.7 Diagnosed incident cases of VTE with chronic kidney disease as a comorbidity
4.4.8 Diagnosed VTE attacks
4.4.9 Number of one- and 10-year first-time recurrent cases of VTE
4.4.10 Number of hospital discharges meeting medically ill criteria
4.4.11 Number of hospital discharges meeting medically ill criteria at risk for VTE
4.4.12 Number of total hip and knee replacements
4.5 Epidemiological forecast for VTE, 2024-2034
4.5.1 Diagnosed incident cases of pulmonary embolism
4.5.2 Diagnosed incident cases of deep vein thrombosis
4.5.3 Diagnosed incident cases of VTE
4.5.4 Age-specific diagnosed incident cases of VTE
4.5.5 Sex-specific diagnosed incident cases of VTE
4.5.6 Diagnosed incident cases of deep vein thrombosis by anatomical region
4.5.7 Number of diagnosed incident cases of VTE by provoking risk factor
4.5.8 One- and 10-year first-time diagnosed recurrent cases of VTE
4.5.9 Diagnosed incident cases of VTE with cancer as a comorbidity
4.5.10 Diagnosed incident cases of VTE with chronic kidney disease as a comorbidity
4.5.11 Number of diagnosed VTE attacks
4.5.12 Number of hospital discharges meeting medically ill criteria at risk for VTE
4.5.13 Total number of hip replacements
4.5.14 Total number of knee replacements
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 Limitations of the analysis
4.6.3 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.1.1 Treatment
5.1.2 Primary prophylaxis
5.2 Key opinion leader insights on disease management
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Mitigating bleeding risk
7.3 Optimal treatment for cancer patients
7.4 Optimal treatment for patients with renal impairment and renal failure
7.5 Complications associated with parenteral therapies
7.6 Improved education among physicians and patients
8 R&D Strategies
8.1 Overview
8.1.1 Development of drugs with novel targets: factor XI inhibitors
8.2 Clinical trial design
8.2.1 Improvements in quantifying and reporting bleeding risk
8.2.2 Need for trial design that accounts for both short- and long-term clinical outcomes
8.2.3 Comparators for clinical trials based in Japan
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - key opinion leaders interviewed for this report
13.4.1 Key opinion leaders
13.5 Primary research - prescriber survey
13.6 About the Authors
13.6.1 Senior Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Reviewers
13.6.5 Vice President of Disease Analysis and Intelligence
13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About the Analyst
- Contact the Publisher
List of Tables
Table 1: VTE - key metrics in the 7MM
Table 2: Risk factors and comorbidities for VTE
Table 3: Treatment guidelines for VTE
Table 4: Top 10 deals by value, 2020-2025
Table 5: VTE market - global drivers and barriers, 2024-2034
Table 6: Key events impacting sales for VTE in the US, 2024-2034
Table 7: VTE market - drivers and barriers in the US, 2024-2034
Table 8: Key events impacting sales for VTE in the 5EU, 2024-2034
Table 9: VTE market - drivers and barriers in the 5EU, 2024-2034
Table 10: Key events impacting sales for VTE in Japan, 2024-2034
Table 11: VTE market - drivers and barriers in Japan, 2024-2034
Table 12: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for VTE in 2024 and 2034
Figure 2: Analysis of the company portfolio gap in VTE during the forecast period
Figure 3:Competitive assessment of the late-stage pipeline agents that the analyst expects to be licensed for the treatment of VTE during the forecast period
Figure 5: Etiology of VTE - Virchow’s triad
Figure 6: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2024
Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PE, DVT, and VTE
Figure 8: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region
Figure 9: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor
Figure 10: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity
Figure 11: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidity
Figure 12: 7MM, sources used to forecast the diagnosed VTE attacks
Figure 13: 7MM, sources used to forecast VTE recurrence after one and 10 years
Figure 14: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE
Figure 15: 7MM, sources used to forecast the primary TKRs and revisions, as well as THRs
Figure 16: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2024
Figure 17: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2024
Figure 18: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2024
Figure 19: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2024
Figure 20: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2024
Figure 21: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2024
Figure 22: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2024
Figure 23: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2024
Figure 24: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2024 and 2034
Figure 25: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2024 and 2034
Figure 26: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2024 and 2034
Figure 27: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, =40 years, 2024
Figure 28: 7MM, THRs, N, both sexes, =15 years, 2024 and 2034
Figure 29: 7MM, TKRs, N, both sexes, =15 years, 2024 and 2034
Figure 30: Treatment algorithm for VTE
Figure 31: Unmet needs and opportunities in VTE
Figure 32: Overview of the development pipeline in VTE
Figure 33: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for VTE in the 7MM during the forecast period
Figure 34: Competitive assessment of the late-stage pipeline agents that the analyst expects to be licensed for the treatment of VTE during the forecast period
Figure 35: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC: NOACs
Figure 36: Analysis of the company portfolio gap in VTE during the forecast period
Figure 37: 7MM sales forecast by country for VTE in 2024 and 2034
Figure 38: Sales forecast by class for VTE treatment in the US in 2024 and 2034
Figure 39: Sales forecast by class for VTE primary prophylaxis in the US in 2024 and 2034
Figure 40: Sales forecast by country for VTE treatment and primary prophylaxis in the 5EU in 2024 and 2034
Figure 41: Sales forecast by class for VTE treatment and primary prophylaxis in the 5EU in 2024 and 2034
Figure 42: Sales forecast by class for VTE treatment in Japan in 2024 and 2034
Figure 43: Sales forecast by class for VTE primary prophylaxis in Japan in 2024 and 2034
